1. Abstracts from the 4th ImmunoTherapy of Cancer Conference: Prague, Czech Republic. 20–22 March 2017. (20th March 2017) Authors: Ženka, J.; Caisová, V.; Uher, O.; Nedbalová, P.; Kvardová, K.; Masáková, K.; Krejčová, G.; Paďouková, L.; Jochmanová, I.; Wolf, K. I.; Chmelař, J.; Kopecký, J.; Loumagne, L.; Mestadier, J.; D'agostino, S.; Rohaut, A.; Ruffin, Y.; Croize, V.; Lemaître, O.; Sidhu, S. S. Journal: Journal for immunotherapy of cancer Issue: Volume 5(2017)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. APG101 blocks pro-apoptotic CD95/CD95L signaling and protects immune cells from activation-induced cell death. (July 2016) Authors: Merz, C.; Sykora, J.; Thamara, B.; Richards, D.; Fricke, H.; Gieffers, C. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. APG101 protects immune cells from activation-induced cell death by blocking pro-apoptotic CD95/CD95L signaling. (December 2016) Authors: Merz, C.; Sykora, J.; Richards, D.M.; Fricke, H.; Gieffers, C. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. APG1233 is a novel hexavalent CD40 agonist acting on monocyte differentiation and macrophage-polarization and promotes increased activation of CD4+ T cells by shifting M1/M2 macrophage balance. (July 2016) Authors: Merz, C.; Sykora, J.; Beyer, T.; Richards, D.; Fricke, H.; Gieffers, C.; Hill, O. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma. (July 2016) Authors: Gieffers, C.; Merz, C.; Sykora, J.; Kunz, C.; Thiemann, M.; Wiestler, B.; Wick, W.; Fricke, H. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Immune cell activation by novel hexavalent CD40 agonist APG1233 compared to trimeric formats or agonistic anti-CD40 antibodies. (December 2016) Authors: Richards, D.M.; Merz, C.; Sykora, J.; Thiemann, M.; Beyer, T.; Kuehn, S.; Fricke, H.; Gieffers, C.; Hill, O. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Wireless physical layer network coding in potential presence of malicious relays – incomplete information game approach. Issue 16 (1st August 2015) Authors: Hynek, T.; Sykora, J. Journal: Electronics letters Issue: Volume 51:Issue 16(2015) Page Start: 1292 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗